Keita Kudo
Osaka, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Efficacy of ipilimumab plus nivolumab with or without chemotherapy according to baseline tumor size: a multicenter retrospective study.
Journal: Translational lung cancer research
Published: February 20, 2026
Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors.
Journal: Cancer research communications
Published: August 24, 2025
Medical Practice Guidelines for Lung Cancers including malignant pleural mesotheliomas and thymic tumors according to evidence-based medicine. 2024. Edited by the Japan Lung Cancer Society. Chapter 3 Guidelines for thymic epithelial tumors - Summary of recommendations.
Journal: Respiratory investigation
Published: August 09, 2025
Impact of B7-H3 and DLL3 expression on the efficacy of PD-L1 blockade therapy in extensive-stage small cell lung cancer.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 03, 2025
A CASE OF IgG4-RELATED DISEASE WITH CONFIRMED RESPONSE TO DUPILUMAB BY SMALL SALIVARY GLAND BIOPSY
Journal: Arerugi = [Allergy]
Published: November 17, 2024
Comparison of immune checkpoint inhibitor plus chemotherapy or ipilimumab plus nivolumab-based therapy for NSCLC patients with PD-L1 TPS (1-49 %): TOPGAN2023-01.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 19, 2024
Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy: Survival analysis with inverse probability weighting from a nationwide, multi-institutional, retrospective study (NEJ047).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 30, 2024
Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer.
Journal: Cancer immunology, immunotherapy : CII
Published: April 28, 2023
Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01).
Journal: Thoracic cancer
Published: August 18, 2022
The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC.
Journal: JTO clinical and research reports
Published: March 12, 2022
Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).
Journal: Thoracic cancer
Published: April 13, 2021
Serum immune modulators during the first cycle of anti-PD-1 antibody therapy in non-small cell lung cancer: Perforin as a biomarker.
Journal: Thoracic cancer
Published: July 05, 2020
Last Updated: 09/26/2026